Bayesian sparse regression for exposure-response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T‐cell leukemia/lymphoma
Abstract Valemetostat is an oral inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1 approved in Japan for the treatment of adult T‐cell leukemia/lymphoma (ATLL). To support the approved daily dose of 200 mg and inform dose adjustments in patients with ATLL, Bayesian exposure-response analyses w...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
Wiley,
2024-10-01T00:00:00Z.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
| Hyllypaikka: |
A1234.567 |
|---|---|
| Nide 1 | Saatavissa |